Phase I and II evaluation of cytembena in disseminated epithelial ovarian cancers and sarcomas.
D000179:Acrylates / Q000009:adverse effects / Q000627:therapeutic use*; D000230:Adenocarcinoma / Q000188:drug therapy; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy; D000328:Adult; D000368:Aged; D003537:Cystadenoma / Q000188:drug therapy; D004341:Drug Evaluation; D004715:Endometriosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy*
D000179:Acrylates